| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5532372 | SUNOVION PHARMS INC | Imide derivatives, and their production and use |
Jul, 2018
(5 years ago) | |
| USRE45573 | SUNOVION PHARMS INC | Process for producing imide compound |
Jun, 2025
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5532372 (Pediatric) | SUNOVION PHARMS INC | Imide derivatives, and their production and use |
Jan, 2019
(5 years ago) | |
| US9174975 | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Feb, 2024
(a month ago) | |
| US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(a month ago) | |
|
US9174975 (Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(3 months from now) | |
|
USRE45573 (Pediatric) | SUNOVION PHARMS INC | Process for producing imide compound |
Dec, 2025
(1 year, 8 months from now) | |
| US8729085 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US8883794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US9907794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
|
US9907794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(2 years from now) | |
|
US8883794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(2 years from now) | |
|
US8729085 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(2 years from now) | |
| US9259423 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(7 years from now) | |
| US9827242 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(7 years from now) | |
|
US9259423 (Pediatric) | SUNOVION PHARMS INC | Method of treatment for mental disorders |
Nov, 2031
(7 years from now) | |
Latuda is owned by Sunovion Pharms Inc.
Latuda contains Lurasidone Hydrochloride.
Latuda has a total of 17 drug patents out of which 4 drug patents have expired.
Expired drug patents of Latuda are:
- US5532372*PED
- US9174975
- US9815827
- US5532372
Latuda was authorised for market use on 07 December, 2011.
Latuda is available in tablet;oral dosage forms.
Latuda can be used as treatment of major depressive episodes associated with bipolar i disorder, treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia, treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder, treatment of schizophrenia with improvement in attention function in schizophrenia, treatment of schizophrenia.
Drug patent challenges can be filed against Latuda from 28 July, 2019.
The generics of Latuda are possible to be released after 23 November, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| M(M-195) | Jan 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
| New Indication(I-674) | Jun 28, 2016 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; Treatment of ...
Dosage: TABLET;ORAL
LATUDA family patents
